Bioventus reports fourth-quarter, full-year 2023 financial results
Click Here to Manage Email Alerts
Key takeaways:
- Bioventus releases its fourth-quarter and full-year 2023 financial report.
- The company reported revenue of $135.4 million for the fourth quarter and $512.3 million for the full year.
Bioventus Inc. has reported its fourth-quarter and full-year 2023 financial results, according to a press release.
Bioventus reported $135.4 million in total revenue for the fourth quarter of 2023, an increase of 7.6% compared with the prior year period, and $512.3 million in total revenue for the full year of 2023, which was even with the full year of 2022.
According to the release, Bioventus updated its full-year 2024 financial guidance, which reflects the company’s revenue growth and improved execution.
“We returned to revenue growth, significantly improved adjusted [earnings before interest, taxes, depreciation and amortization], and further enhanced our liquidity position as a result of our team’s strong execution in the fourth quarter of 2023,” Rob Claypoole, president and CEO of Bioventus, said in the release.
“After immersing myself in the business over the last 2 months, it’s clear to me that Bioventus has a solid foundation of market-leading products and compelling growth prospects. Going forward, we remain committed to unlocking our full potential to help patients and create value for shareholders,” Claypoole said.
Read more about
Click Here to Manage Email Alerts